Know Cancer

or
forgot password

Phase 1 Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia


Phase 1
18 Years
N/A
Not Enrolling
Both
Myeloid Leukemia

Thank you

Trial Information

Phase 1 Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia


Inclusion Criteria:



- Must understand and voluntarily sign an informed consent form.

- Must be greater than or equal to 18 years of age at the time of signing the informed
consent form.

- Must have a diagnosis of high-risk myeloid leukemia, defined as:

1. Subjects > 70 years of age with newly diagnosed acute myelogenous leukemia (AML)
(regardless of karyotype) who decline conventional induction chemotherapy;

2. Subjects > 60 years of age with newly diagnosed AML and poor-risk cytogenetics
or a history of secondary AML who decline conventional induction chemotherapy;

3. Subjects with newly diagnosed AML who do not experience a CR after at least 2
cycles of induction chemotherapy;

4. Subjects with AML who do not experience a second or greater complete remission
after 1 but no more than 2 cycles of re-induction chemotherapy;

5. Subjects with recurrence of AML after a remission duration of less than three
months in subjects < 60 years of age or remission duration of less than six
months in subjects > 60 years of age; or

6. Subjects with imatinib-refractory chronic myeloid leukemia (CML) in blast crisis
defined as > 30% blasts and promyelocytes in the peripheral blood or bone marrow
smear despite treatment with imatinib > 600 mg/daily

- ECOG performance status < 2 (see Appendix 2).

- Serum creatinine < 2 mg/d and ALT (SGPT), alkaline phosphatase, and conjugated
bilirubin < 2 times the upper limit of normal.

- No conventional or investigational anti-leukemic treatment within two weeks of the
administration of study drug with the exception of hydroxyurea to control the
peripheral blood blast count.

- Subjects must have recovered from any prior treatment-related toxicities.

- Subject must be able to adhere to the study visit schedule and other protocol
requirements.

- Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy
test within 7 days of starting study drug. In addition, sexually active WCBP must
agree to use adequate contraceptive methods (oral, injectable, or implantable
hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive
with spermicide; or vasectomized partner) while on study drug. WCBP must agree to
have pregnancy tests every 4 weeks while on study drug.

- Males (including those who have had a vasectomy) must use barrier contraception
(latex condoms) when engaging in reproductive sexual activity with WCBP while on
study medication and 4 weeks after the last dose of study medication

Exclusion Criteria:

- Subjects with central nervous system (CNS) involvement as documented by spinal fluid
cytology or imaging; individuals with signs or symptoms of leukemic meningitis or a
history of leukemic meningitis must have a negative lumbar puncture within 2 weeks
prior to enrollment in the study.

- Subjects who are pregnant or lactating; women of child-bearing potential must have a
negative urine or serum pregnancy test within 14 days prior to the initial treatment
with CC-401.

- Subjects with severe or life threatening active, unresolved systemic infections.

- Prior history of malignancy other than myeloid leukemia (except basal cell or
squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the
subject has been free of disease for ≥ 3 years.

- Known HIV-1 positivity.

- Known hepatitis B surface antigen (HBsAg) positivity.

- Prior treatment with CC-401

- Use of any other experimental drug or treatment within 28 days of baseline

- Inability to provide a bone marrow aspirate

- Subjects with severe or life-threatening active bleeding refractory to platelet
transfusion

- Subjects with severe or life-threatening anemia refractory to red blood cell
transfusion

- Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent form.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Authority:

United States: Food and Drug Administration

Study ID:

CC-401-AML-001

NCT ID:

NCT00126893

Start Date:

October 2005

Completion Date:

September 2006

Related Keywords:

  • Myeloid Leukemia
  • Leukemia
  • AML
  • CC401
  • CC-401
  • Celgene
  • High Risk Myeloid Leukemia
  • Myeloid Leukemia
  • Leukemia
  • Leukemia, Myeloid

Name

Location

Indiana University Medical CenterIndianapolis, Indiana  46202